{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.63","upperLimit":"80.59","value":"25.0"},{"groupId":"OG001","lowerLimit":"13.22","upperLimit":"48.67","value":"28.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"title":"Week 12: GH: ≥ 1 - ≤ 2.5 μg/L @ screening"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.63","upperLimit":"80.59","value":"25.0"},{"groupId":"OG001","lowerLimit":"21.50","upperLimit":"59.42","value":"39.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"title":"Week 24: GH: ≥ 1 - ≤ 2.5 μg/L @ screening"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.63","upperLimit":"80.59","value":"25.0"},{"groupId":"OG001","lowerLimit":"24.46","upperLimit":"62.82","value":"42.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"title":"Week 36: GH: ≥ 1 - ≤ 2.5 μg/L @ screening"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.19","upperLimit":"36.03","value":"7.7"},{"groupId":"OG001","lowerLimit":"1.75","upperLimit":"11.98","value":"5.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"94"}],"units":"Participants"}],"title":"Week 12: GH: > 2.5 μg/L @ screening"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.19","upperLimit":"36.03","value":"7.7"},{"groupId":"OG001","lowerLimit":"1.75","upperLimit":"11.98","value":"5.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"94"}],"units":"Participants"}],"title":"Week 24: GH: > 2.5 μg/L @ screening"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.19","upperLimit":"36.03","value":"7.7"},{"groupId":"OG001","lowerLimit":"2.38","upperLimit":"13.38","value":"6.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"94"}],"units":"Participants"}],"title":"Week 36: GH: > 2.5 μg/L @ screening"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"97.50","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Week 12: GH: Missing"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"97.50","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Week 24: GH: Missing"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"97.50","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Week 36: GH: Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"123"}],"units":"Participants"}],"description":"Percentage of participants achieving GH \\<1 μg/L and IGF-1 \\<ULN at weeks 12 and 24 overall and by GH level at screening.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who were part of the run-in phase, i.e. group 1)","id":"OG000","title":"Pasireotide LAR (run-in Phase)"},{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.","id":"OG001","title":"Pasireotide LAR Overall"}],"paramType":"NUMBER","populationDescription":"FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.","reportingStatus":"POSTED","timeFrame":"Week 12, Week 24, Week 36","title":"Core Phase: Percentage of Participants With Mean GH <1 μg/L and IGF-1 <ULN","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}